Literature DB >> 15313896

The increased expression of peroxisome proliferator-activated receptor-gamma1 in human breast cancer is mediated by selective promoter usage.

Xin Wang1, R Chase Southard, Michael W Kilgore.   

Abstract

Peroxisome proliferator-activated receptor-gamma1 (PPARgamma1) is transactivated by a wide range of ligands in normal human mammary epithelial and breast cancer cells. Although transactivation of PPARgamma mediates the expression of genes that are markers of differentiation, its overexpression in cancers of the breast, thyroid, colon, and lung suggests its dysregulation may play a role in oncogenesis, cancer progression, or both. We report the overexpression of PPARgamma is caused by the use of a tumor-specific promoter in breast cancer cells that is distinct from the promoter used in normal epithelia. Thus, the increase in PPARgamma expression seen in breast cancer cells results from promoter recruitment, providing new insights into the expression and actions of PPARgamma in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15313896     DOI: 10.1158/0008-5472.CAN-04-0043

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation.

Authors:  Cameron N Johnstone; Perry S Mongroo; A Sophie Rich; Michael Schupp; Mark J Bowser; Andrew S Delemos; John W Tobias; Yingqiu Liu; Gregory E Hannigan; Anil K Rustgi
Journal:  Mol Cell Biol       Date:  2007-11-12       Impact factor: 4.272

2.  Fluorine-18 labeling and biodistribution studies on peroxisome proliferator-activated receptor-gamma ligands: potential positron emission tomography imaging agents.

Authors:  Byung Chul Lee; Carmen S Dence; Haibing Zhou; Ephraim E Parent; Michael J Welch; John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2009-02       Impact factor: 2.408

3.  Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells.

Authors:  Daniela Bonofiglio; Erika Cione; Hongyan Qi; Attilio Pingitore; Mariarita Perri; Stefania Catalano; Donatella Vizza; Maria Luisa Panno; Giuseppe Genchi; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Am J Pathol       Date:  2009-07-30       Impact factor: 4.307

4.  MAZ drives tumor-specific expression of PPAR gamma 1 in breast cancer cells.

Authors:  Xin Wang; R Chase Southard; Clinton D Allred; Dominique R Talbert; Melinda E Wilson; Michael W Kilgore
Journal:  Breast Cancer Res Treat       Date:  2007-09-28       Impact factor: 4.872

5.  Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells.

Authors:  Ping Fan; Balkees Abderrahman; Tina S Chai; Smitha Yerrum; V Craig Jordan
Journal:  Mol Cancer Ther       Date:  2018-09-17       Impact factor: 6.261

6.  Mechanisms Mediating the Effects of γ-Tocotrienol When Used in Combination with PPARγ Agonists or Antagonists on MCF-7 and MDA-MB-231 Breast Cancer Cells.

Authors:  Abhita Malaviya; Paul W Sylvester
Journal:  Int J Breast Cancer       Date:  2013-01-28

7.  Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.

Authors:  Linah Al-Alem; R Chase Southard; Michael W Kilgore; Thomas E Curry
Journal:  PLoS One       Date:  2011-01-21       Impact factor: 3.240

8.  A Role for the PPARgamma in Cancer Therapy.

Authors:  Moray J Campbell; Carsten Carlberg; H Phillip Koeffler
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

9.  Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells.

Authors:  Yekaterina Y Zaytseva; Xin Wang; R Chase Southard; Natalie K Wallis; Michael W Kilgore
Journal:  Mol Cancer       Date:  2008-12-05       Impact factor: 27.401

10.  Synergistic Antiproliferative Effects of Combined γ -Tocotrienol and PPAR γ Antagonist Treatment Are Mediated through PPAR γ -Independent Mechanisms in Breast Cancer Cells.

Authors:  Abhita Malaviya; Paul W Sylvester
Journal:  PPAR Res       Date:  2014-03-04       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.